Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine

Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that MAR001, a monoclonal antibody targeting ANGPTL4, met all objectives in Phase 2b TYDAL-TIMI 78 trial for severe hypertriglyceridemia treatment. The drug achieved placebo-adjusted triglyceride reductions of 39.1%-45.5% across doses at Week 12, with up to 72.2% reduction in participants with baseline triglycerides ≥500 mg/dL. The drug demonstrated a favorable safety profile with no worsening of HbA1c. Results were presented at AHA 2026 and published in The New England Journal of Medicine.